Bharucha David 4
4 · Milestone Pharmaceuticals Inc. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
Milestone (MIST) CMO David Bharucha Receives Equity Awards
What Happened
David Bharucha, Chief Medical Officer of Milestone Pharmaceuticals (MIST), received equity awards on Feb 2, 2026: a grant of 204,000 derivative option units and 136,000 restricted stock units (RSUs), for a total of 340,000 contingent shares. Both awards are reported at $0 (no cash paid). These are grants (not open-market purchases or sales) and therefore represent deferred compensation rather than immediate buying or selling of shares.
Key Details
- Transaction date: February 2, 2026; Form 4 filed Feb 4, 2026 (no late filing indicated).
- Grants reported: 204,000 derivative units (option award) and 136,000 RSUs; reported price $0.00.
- Total contingent shares: 340,000.
- Shares owned after transaction: not specified in the provided filing details.
- Footnotes:
- F1 (options): 1/4 of option shares vest on Feb 2, 2027, then 1/36 of the remaining monthly thereafter, contingent on continued service.
- F2 (RSUs): each RSU converts to one common share upon vesting.
- F3 (RSU vesting): RSUs vest 1/4 on each of Feb 2 in 2027, 2028, 2029 and 2030, subject to continued service.
Context
- The 204,000 derivative units are option-like awards (not an exercise); no immediate shares were issued or sold.
- The 136,000 RSUs are a promise to deliver shares in the future if vesting conditions are met.
- Grants are routine compensation for executives and are informational rather than a direct market sentiment signal.
Insider Transaction Report
Form 4
Bharucha David
Chief Medical Officer
Transactions
- Award
Employee Stock Option (right to buy)
[F1]2026-02-02+204,000→ 204,000 totalExercise: $1.97Exp: 2036-02-02→ Common Shares (204,000 underlying) - Award
Restricted Stock Unit
[F2][F3]2026-02-02+136,000→ 136,000 total→ Common Shares (136,000 underlying)
Footnotes (3)
- [F1]One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
- [F2]Each restricted stock unit represents a contingent right to receive one common share.
- [F3]One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date.
Signature
/s/ Joseph Oliveto, Attorney-in-Fact|2026-02-04